Immunotherapeutic efficacy of recombinant canine IL-15 as an adjunct to chemotherapy in canine lymphoma
Adjunctive rcIL-15 therapy improved tumor response, reduced biomarker levels, and enhanced QOL with an acceptable safety profile. These findings support the potential of rcIL-15 as a safe and effective immunotherapeutic adjunct for canine lymphoma, meriting further investigation in larger-scale trials.
Authors
- Kye-Young Koh (ORCID: https://orcid.org/0000-0002-3488-3062)
- Sang‐Ki Kim (ORCID: https://orcid.org/0000-0003-0292-8200)
- Min‐Hee Kang (ORCID: https://orcid.org/0000-0001-7304-5064)
- Jae‐Il Lee (ORCID: https://orcid.org/0000-0002-1066-0980)
- Hee‐Myung Park (ORCID: https://orcid.org/0000-0002-7254-9524)
- Miae Kang
Institutions
- Konkuk University (KR)
- Jangan University (KR)
- Genexine (South Korea) (KR)
- Gwangju University (KR)
Publication Details
- Journal
- Frontiers in Veterinary Science
- Published
- 2025-05-30
- DOI
- https://doi.org/10.3389/fvets.2025.1596084
- Primary Topic
- Veterinary Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00